



**Interpretation of HbA<sub>1c</sub>: analytical and clinical problems**

Andrea Mosca

Centro per la Riferibilità metrologica in Medicina di Laboratorio  
Dip. Fisiopatologia medico-chirurgica e dei trapianti  
Università degli Studi di Milano

- \* references
- \* pre-analytical phase
- \* analytical phase
- \* post-analytical phase
- \* future

**\*agenda**

A. Mosca - UniMI 2

- \* references
- \* pre-analytical phase
- \* analytical phase
- \* post-analytical phase
- \* future

**\*agenda**

A. Mosca - UniMI 3

Clinical Chemistry 57:6  
e1-e47 (2011)

**Special Report**

**Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus**

David B. Sacks,<sup>1\*</sup> Mark Arnold,<sup>2</sup> George L. Bakris,<sup>3</sup> David E. Bruns,<sup>4</sup> Andrea Rita Horvath,<sup>5</sup> M. Sue Kirkman,<sup>6</sup> Ake Lernmark,<sup>7</sup> Boyd E. Metzger,<sup>8</sup> and David M. Nathan<sup>9</sup>

4

- \* references
- \* pre-analytical phase
- \* analytical phase
- \* post-analytical phase
- \* future

## \* agenda

A. Mosca - UniMI

5

## \* Advantages of HbA<sub>1c</sub> for diagnosis of diabetes

- \* 1. Indicates long-term blood glucose concentration
- \* 2. Fasting not necessary
- \* 3. Sample may be obtained any time of day
- \* 4. Sample stable
- \* 5. Low intra-individual variability
- \* 6. Not altered by acute factors eg, stress, exercise
- \* 7. Assay standardised across instruments
- \* 8. Concentration predicts the development of microvascular complications

A. Mosca - UniMI

6

## \* Disadvantages of HbA<sub>1c</sub> for diagnosis of diabetes

- \* 1. Cost (?)
- \* 2. May not be available in some areas of world
- \* 3. May be altered by factors other than glucose (e.g., change in RBC lifespan, ethnicity)
- \* 4. Some conditions may interfere with measurement
  - \* Carbamylated Hb
  - \* Labile A1c
  - \* Fetal Hb
  - \* Hb variants

A. Mosca - UniMI

7





## \* When HbA<sub>1c</sub> should not be used for diagnosis

- Children and adolescents
- Women until 2 months postpartum
- People with suspicion of type 1 diabetes (all ages)
- People with acute diabetes symptoms
- Prediabetes with acute stress hyperglycemia (f.e. stroke, MI, organ donor)
- People with drugs (<2 months), which are leading to an acute increase of plasma glucose (glucocorticoids, psychopharmacological drugs)
- Shortly after pancreas surgery, acute pancreatitis
- People with HIV infection
- Endstage renal disease

A. Mosca - UniMI

8

R. Landgraf (by courtesy)



## \* Races and HbA<sub>1c</sub>

**HbA<sub>1c</sub> is higher, respect to Caucasian:**

- Afro-Americans ~ 8 mmol/mol
- Latinos ~ 5
- Punjabi Sikhs ~ 4
- Asian ~ 3

\*KIRK et al. Diabetes Care 2006; 29:2130-2136  
 \*Likhari T, Gama R. Diabetic Med 2009; 26:1068-1069  
 \*Herman et al. J Clin Endocrinol Metab 2009;94:1689-1694  
 \*Kamps et al. Diabetes Care 2010;33:1025-1027  
 \*Wolfenbuttel et al. Diabetes Care 2013;36:2931-2936

A. Mosca - UniMI 13

## \* Nutrition and HbA<sub>1c</sub>

- Alcohol from abstinence to heavy drinker:  
HbA<sub>1c</sub> drop of ~0.4%  
The Kaiser Permanente Northern California Diabetes Registry  
Ahmed et al. J Gen Intern Med 2008; 23:275-82
- The lower the fat consumption and the higher  
the percentage of unsaturated free fatty acids  
the lower HbA<sub>1c</sub>: ~0.2% - 0.3%  
Harding et al.: Diabetes Care 2001;24:1911-1916

A. Mosca - UniMI 14

R. Landgraf (by courtesy)

### Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA<sub>1c</sub>

CV ~ 12 %

Cohen, Blood 2009;112:4284-91

### RESEARCH ARTICLE

#### Impact of common genetic determinants of Hemoglobin A<sub>1c</sub>

A. Mosca - UniMI 16

PLOS MEDICINE

# \*Diabetes epidemics and Hemoglobinopathies

**Diabetes growth 2000 - 2030**

**Hemoglobin disorders incidence (per 1000 new births)**

Hossain et al, NEJM 2007;356:213-5  
Modell et al, Bulletin of the World Health Organization 2008;86:480-7

A. Mosca - UNIMI 17

## Harmonizing Hemoglobin A<sub>1c</sub> Testing

A better A<sub>1c</sub> test means better diabetes care

**HbA<sub>1c</sub> Assay Interferences**

HbA<sub>1c</sub> methods: Effects of Hemoglobin Variants (HbC, HbS, HbE and HbD traits) and Elevated Fetal Hemoglobin (HbF)  
Updated September 2014

More comprehensive information regarding HbA<sub>1c</sub> assay interferences

HbA<sub>1c</sub>, also called A<sub>1c</sub>, is a measure of the amount of glucose attached to hemoglobin (Hb) in red blood cells. The higher the glucose levels over the previous 2-3 months, the higher the A<sub>1c</sub>. The A<sub>1c</sub> test is used to monitor the glucose levels of patients who have been diagnosed with diabetes. In people who have hemoglobin variants such as HbS (sickle cell trait), some A<sub>1c</sub> tests give falsely high or low readings that can lead to the over-treatment or under-treatment of diabetes.

Laboratories use many different methods for measuring A<sub>1c</sub>, but some of these methods can give inaccurate results when the patient has a hemoglobin variant such as sickle cell trait or if there is an elevated level of fetal hemoglobin (HbF). Doctors or patients interested in getting information about the accuracy of a particular A<sub>1c</sub> method for patients with hemoglobin variants should first find out which method your laboratory is using.

The following table lists the 20 methods most often used to measure A<sub>1c</sub> and whether the method is affected by HbC, HbS, HbE or HbD trait or by elevated HbF. Methods are listed in alphabetical order by manufacturer. The criteria used to determine whether or not a method shows interference that is clinically significant (indicated by "Yes") is >=7% at 6 and/or 9% A<sub>1c</sub>. If your diabetes patient has a hemoglobin variant, your lab should use a method that does not show interference from that variant in order to produce an accurate A<sub>1c</sub> result.

Method	Interference from HbC	Interference from HbS	Interference from HbE	Interference from HbD	Interference from elevated HbF
Abbott Architect/Aerostat	Yes	Yes	@	@	\$
Alicya ADAMS A1c A. Woollam Unimed	No	No	HbA1c not quantified	HbA1c not quantified	No <30% HbF
Axis-Shield Afinion	No	No	No	No	\$

**\*Prevalence of anemia in diabetic patients UK experiences (Teesside)**

n = 7331

Jones et al, Diabetic Medicine 2010; 27:655-9

A. Mosca - UNIMI

Clinica Chimica Acta  
Volume 478, March 2018, Pages 57-61

**Effect of iron supplementation on HbA<sub>1c</sub> levels in pregnant women with and without anaemia**

Paula Breitenbach Renz<sup>a</sup>, Mayana Kieling Hernandez<sup>a</sup>, Joiza Lins Camargo<sup>a, b, c, d, e</sup>

<https://doi.org/10.1016/j.cca.2017.12.028> [Get rights and content](#)

**Highlights**

- The effect of iron supplementation (IS) on HbA<sub>1c</sub> levels in nondiabetic pregnant women was studied.
- IS in pregnant women without anaemia or with mild anaemia has no effect HbA<sub>1c</sub> levels.
- Interpreting HbA<sub>1c</sub> results in pregnancy during IS and moderate or severe anaemia still requires caution.

A. Mosca

### Glycated haemoglobin and iron deficiency anaemia: a case-control study

Jani Intra<sup>1</sup>  
MD  
Giuseppe Lisonta<sup>1</sup>  
MD  
Fabrizio Cappellini<sup>1</sup>  
D  
María Bartosa<sup>1</sup>  
MD  
Paolo Brambilla<sup>1</sup>  
MD

<sup>1</sup>Department of Laboratory Medicine, University of Milano-Bicocca, Sesto Hospital, Sesto (MI), Italy

Correspondence to: Jani Intra, Department of Laboratory Medicine, University of Milano-Bicocca, Sesto Hospital, via Venezia 1, 20051 Sesto MI, Italy

**Abstract**  
Several studies have suggested an association between iron deficiency anaemia and higher HbA<sub>1c</sub> levels, but the results are conflicting and the matter is under debate. We conducted a retrospective case-control study to investigate both the effect of iron deficiency and the reduction of haemoglobin level on HbA<sub>1c</sub> measurement in subjects with iron deficiency anaemia.

Measured haemoglobin concentration range (g/dL)	Percentage decrease of HbA <sub>1c</sub> (mmol/mol) supposing a normal haemoglobin concentration of 13g/dL (median [5th/95th percentile])*	Lower glycated haemoglobin values in the case of HbA <sub>1c</sub> 48mmol/mol (median [5th/95th percentile])**
7.0–8.0	-4.2 (-4.6/-3.9)	45.98 (45.79/46.13)
8.1–9.0	-3.3 (-3.7/-2.9)	46.41 (46.22/46.46)
9.1–10.0	-2.6 (-2.9/-2.3)	46.75 (46.61/46.90)
10.1–11.0	-1.9 (-2.2/-1.6)	47.09 (46.94/47.23)
11.1–12.0	-1.2 (-1.5/-0.8)	47.42 (47.28/47.62)
12.1–13.0	-0.3 (-0.7/0.0)	47.86 (47.66/48.00)

\*These corrections should be applied to HbA<sub>1c</sub> levels obtained using ion-exchange HPLC ARKRAY ADAMS A<sub>1c</sub> series HA (Menarini Diagnostics, Firenze, Italy) haemoglobin analysers.  
\*\*Reduction of the cut-off HbA<sub>1c</sub> 48mmol/mol at different haemoglobin concentrations using estimated percentage differences between measured and estimated HbA<sub>1c</sub> values.



Table 3. Estimated correction of HbA<sub>1c</sub> values

A. Mosca - UniMI

- \* references
- \* pre-analytical phase
- \* analytical phase
- \* post-analytical phase
- \* future

\*agenda

A. Mosca - UniMI 22



**CONCLUSIONS:** The state of the art is that 1 of 20 laboratories does not meet the IFCC criterion, but there are substantial differences between country and between manufacturer groups. Efforts to further improve quality should focus on reducing between-laboratory variation.

With some limitations, fresh whole blood and well-defined lyophilized specimens are suitable for purpose.

A. Mosca - UniMI 25

- \* references
  - \* pre-analytical phase
  - \* analytical phase
  - \* post-analytical phase
  - \* future
- \*agenda
- A. Mosca - UniMI 26

**Refertazione dell'emoglobina glicata in presenza di varianti emoglobiniche**


Mariarosa Carta<sup>1</sup>, Renata Palearì, Anna Caldini<sup>2</sup>, Alessandro Terreni<sup>3</sup>, Andrea Mosca<sup>2</sup> per il Gruppo di Studio Intersocietario SIBioC-SIMeL Diabete Mellito

<sup>1</sup>Laboratorio di Chimica Clinica ed Ematologia, ULSS 6, Vicenza  
<sup>2</sup>Dipartimento di Scienze e Tecnologie Biomediche, Università degli Studi di Milano  
<sup>3</sup>Laboratorio Generale, Azienda Ospedaliero-Universitaria Careggi, Firenze

**ABSTRACT**  
 Glycated hemoglobin reporting in presence of hemoglobin variants. Measurement of glycated hemoglobin

Carta et al, Biochim Clin 2011;35:42-5

A. Mosca - UniMI 27



- \* references
- \* pre-analytical phase
- \* analytical phase
- \* post-analytical phase
- \* future

\*agenda

A. Mosca - UniMI 29

1.) Fall, 2014:  $M_{RBC} = 45$  days

2.) Fall, 2015:  $HbA1c = 8.1\%$

3.) Fall, 2015:  $AG = ?$

Measurement: 210 mg/dl  
Model estimate: 209 mg/dl  
Current estimate: 186 mg/dl

SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE

DIABETES  
Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring

Roy Makku,<sup>1\*</sup> David M. Nathan,<sup>1\*</sup> John M. Higgins<sup>1,2\*</sup>

A. Mosca - UniMI 30

Average glucose prediction

Ross Molinaro

times:

60, 80, 100, 120, 140

RCL

HbA1<sub>c</sub> (IFCC) (mmol/mol)

HbA1<sub>c</sub> (NGSP) (%)


A. Mosca - UniMI 31 Clinica Chimica Acta 474 (2017) 124-129

Contents lists available at ScienceDirect

Conclusions: Model calculations predict the relationship between changes in estimated average glucose to changes in operative glucose for serial A1c measurements made at intervals <120days. Given that serial measurements of A1c made at short intervals are not uncommon in practice, physicians may find this information to be useful.

A. Mosca - UniMI 32 Clinical Biochemistry 54 (2018) 73-77





**\*Summary**

- \* HbA<sub>1c</sub> is still the most relevant parameter for monitoring the glycemic control
- \* The Hb variants causing altered red cell lifespan or glycation rate affect results regardless of assay methodology
- \* Red cell enzymopathies and red cell membrane disorders may cause also major pre-analytical interference
- \* Investigate any result that does not match clinical impression or discordant with other parameters for glucose monitoring.

A. Mosca - UniMI 34

**Standardization of HbA<sub>1c</sub>: are all the pieces in place?**

- Top of the chain: YES (IFCC Network)
- Middle: probably YES (information not uniform and difficult to be released)
  - Bottom: difficult to draw objective evidences (depending on country and rules); more efforts needed to achieve standardization overall

A. Mosca - UniMI 35

**\*What next?**

- Always use the best method
- Consensus on interpretation
- Need for more information available to the laboratory (partitioned reference ranges)
- More studies on glycation kinetics
- Education and communication (time for personalized medicine?)

A. Mosca - UniMI 36

Centro Interdipartimentale per la  
Riferibilità Metrologica in Medicina di  
Laboratorio (CIRME)

Under the auspices of:

 Accurate results  
for patient care

12<sup>th</sup> International Scientific Meeting  
**STANDARDIZATION IN  
LABORATORY MEDICINE  
AND PATIENT SAFETY**

 EVERY DAY IS  
**PATIENT SAFETY  
DAY**

A. Mosca - UniMI

MILANO, ITALY  
November 29<sup>th</sup>, 2018